行情

CVM

CVM

CEL SCI
AMEX
3.380
-0.100
-2.87%
已收盘, 17:23 10/05 EDT
开盘
3.400
昨收
3.480
最高
3.470
最低
3.360
成交量
9.51万
成交额
--
52周最高
12.82
52周最低
2.490
市值
1.47亿
市盈率(TTM)
-3.9634
分时
5日
1月
3月
1年
5年
Cel-Sci 报告了新辅助多因子在局部晚期头颈癌中的 3 期研究的积极数据
Cel-Sci 报告了新辅助多因子在局部晚期头颈癌中的 3 期研究的积极数据
MT Newswires · 09/12 13:12
CVM 简况
CEL-SCI Corporation is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are LEAPS COV-19, CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company is developing an immunotherapy with the potential to treat the coronavirus (COVID-19) using its LEAPS peptide technology.

微牛提供CEL-SCI Corporation(AMEX-CVM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CVM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CVM股票基本功能。